OTCMKTS:CPHRF Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis $12.39 -0.21 (-1.67%) As of 03:42 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's Range$12.39▼$12.3950-Day Range$10.59▼$14.3452-Week Range$8.54▼$15.00Volume3,417 shsAverage Volume5,627 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America. In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). These include dry-powder inhalers (DPIs) and metered-dose inhalers (MDIs) that offer patients lower-cost alternatives to branded drugs. In dermatology, the company has brought to market treatments addressing acne, fungal infections of the nails and other skin disorders, often through licensing agreements with innovator companies. Cipher operates primarily in Canada and the United States. Its business model emphasizes strategic partnerships and licensing arrangements, enabling the company to secure exclusive Canadian rights to new products while collaborating with third-party partners for U.S. commercialization. This approach allows Cipher to leverage established regulatory approvals and focus resources on market access, sales and marketing. Looking ahead, Cipher continues to expand its product pipeline through in-licensing and development of both generic and branded prescription drugs. The company is advancing new formulations in respiratory care and exploring additional dermatology assets, aiming to build a diversified specialty pharmaceutical portfolio that delivers growth through product launches and ongoing royalty streams.AI Generated. May Contain Errors. Read More Receive CPHRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPHRF Stock News HeadlinesCaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)April 7, 2026 | businesswire.comCipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 13, 2026 | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 19 at 1:00 AM | Brownstone Research (Ad)Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)January 28, 2026 | finance.yahoo.comDiscovering Canada's Undiscovered Gems In January 2026January 22, 2026 | finance.yahoo.comCipher Pharmaceuticals Has PotentialNovember 23, 2025 | seekingalpha.comCipher Pharmaceuticals Inc (CPHRF) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...November 8, 2025 | finance.yahoo.comCipher Pharmaceuticals Reports Third Quarter 2025 ResultsNovember 7, 2025 | ca.finance.yahoo.comSee More Headlines CPHRF Stock Analysis - Frequently Asked Questions How have CPHRF shares performed this year? Cipher Pharmaceuticals' stock was trading at $10.98 at the beginning of the year. Since then, CPHRF shares have increased by 12.8% and is now trading at $12.3899. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) announced its quarterly earnings data on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.06. The firm earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/05/2016Today5/19/2026Next Earnings (Estimated)8/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CIKN/A Webwww.cipherpharma.com Phone(905) 602-5840FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:CPHRF) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.